Tore Haslemo

1.3k total citations
37 papers, 919 citations indexed

About

Tore Haslemo is a scholar working on Pharmacology, Psychiatry and Mental health and Pharmacology. According to data from OpenAlex, Tore Haslemo has authored 37 papers receiving a total of 919 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pharmacology, 23 papers in Psychiatry and Mental health and 11 papers in Pharmacology. Recurrent topics in Tore Haslemo's work include Pharmacogenetics and Drug Metabolism (26 papers), Schizophrenia research and treatment (17 papers) and Treatment of Major Depression (10 papers). Tore Haslemo is often cited by papers focused on Pharmacogenetics and Drug Metabolism (26 papers), Schizophrenia research and treatment (17 papers) and Treatment of Major Depression (10 papers). Tore Haslemo collaborates with scholars based in Norway, Sweden and Serbia. Tore Haslemo's co-authors include Espen Molden, Magnus Ingelman‐Sundberg, Marin M. Jukić, Robert L. Smith, Helge Refsum, Lars Tanum, Erik Eliasson, H. Refsum, Marianne Kristiansen Kringen and Kristine Hole and has published in prestigious journals such as American Journal of Psychiatry, Neuropsychopharmacology and Clinical Pharmacology & Therapeutics.

In The Last Decade

Tore Haslemo

34 papers receiving 894 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tore Haslemo Norway 19 461 456 221 192 124 37 919
Werner Steimer Germany 22 391 0.8× 512 1.1× 315 1.4× 274 1.4× 140 1.1× 51 1.3k
Margaret T. Susce United States 18 557 1.2× 450 1.0× 198 0.9× 129 0.7× 109 0.9× 19 1.2k
J. Brockmöller Germany 7 256 0.6× 778 1.7× 252 1.1× 250 1.3× 230 1.9× 9 1.1k
Sara Ramos Spain 10 311 0.7× 388 0.9× 97 0.4× 162 0.8× 121 1.0× 11 750
Roos van Westrhenen Netherlands 15 270 0.6× 236 0.5× 119 0.5× 146 0.8× 49 0.4× 40 1.1k
Kazuo Mihara Japan 24 989 2.1× 589 1.3× 333 1.5× 343 1.8× 229 1.8× 89 1.6k
Ida Rudberg Norway 9 198 0.4× 285 0.6× 102 0.5× 173 0.9× 87 0.7× 11 631
Josiah D. Allen United States 13 291 0.6× 596 1.3× 231 1.0× 321 1.7× 29 0.2× 21 888
Nada Božina Croatia 23 386 0.8× 482 1.1× 355 1.6× 166 0.9× 423 3.4× 86 1.5k
Pablo Zubiaur Spain 17 171 0.4× 332 0.7× 164 0.7× 97 0.5× 130 1.0× 73 877

Countries citing papers authored by Tore Haslemo

Since Specialization
Citations

This map shows the geographic impact of Tore Haslemo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tore Haslemo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tore Haslemo more than expected).

Fields of papers citing papers by Tore Haslemo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tore Haslemo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tore Haslemo. The network helps show where Tore Haslemo may publish in the future.

Co-authorship network of co-authors of Tore Haslemo

This figure shows the co-authorship network connecting the top 25 collaborators of Tore Haslemo. A scholar is included among the top collaborators of Tore Haslemo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tore Haslemo. Tore Haslemo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hole, Kristine, et al.. (2024). Dose-dependent effect of lamotrigine on quetiapine serum concentration in patients using instant release tablets. European Journal of Clinical Pharmacology. 80(6). 839–845.
2.
Hole, Kristine, et al.. (2023). Effect of CYP2D6 genotype on duloxetine serum concentration. Basic & Clinical Pharmacology & Toxicology. 134(1). 186–192. 5 indexed citations
3.
Haslemo, Tore, et al.. (2022). Genotyping of patients treated with selective serotonin reuptake inhibitors. Tidsskrift for Den norske legeforening. 142(13). 3 indexed citations
4.
5.
Haslemo, Tore, Marin M. Jukić, Maxim Ivanov, et al.. (2021). A Novel CYP2C‐Haplotype Associated With Ultrarapid Metabolism of Escitalopram. Clinical Pharmacology & Therapeutics. 110(3). 786–793. 31 indexed citations
6.
Kringen, Marianne Kristiansen, et al.. (2020). The Influence of Combined CYP2D6 and CYP2C19 Genotypes on Venlafaxine and O-Desmethylvenlafaxine Concentrations in a Large Patient Cohort. Journal of Clinical Psychopharmacology. 40(2). 137–144. 22 indexed citations
7.
Haslemo, Tore, et al.. (2019). Impact of CYP2C19 genotype on sertraline exposure in 1200 Scandinavian patients. Neuropsychopharmacology. 45(3). 570–576. 28 indexed citations
8.
Jukić, Marin M., Robert L. Smith, Tore Haslemo, Espen Molden, & Magnus Ingelman‐Sundberg. (2019). Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study. The Lancet Psychiatry. 6(5). 418–426. 113 indexed citations
9.
Smith, Robert L., Tore Haslemo, Ole A. Andreassen, et al.. (2017). Correlation Between Serum Concentrations of N-Desmethylclozapine and Granulocyte Levels in Patients with Schizophrenia: A Retrospective Observational Study. CNS Drugs. 31(11). 991–997. 19 indexed citations
10.
Haslemo, Tore, et al.. (2016). Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients. SpringerPlus. 5(1). 350–350. 4 indexed citations
11.
Hole, Kristine, et al.. (2016). Impact of genetic and nongenetic factors on interindividual variability in 4β-hydroxycholesterol concentration. European Journal of Clinical Pharmacology. 73(3). 317–324. 19 indexed citations
12.
Smith, Robert L., Tore Haslemo, H. Refsum, & Espen Molden. (2016). Impact of age, gender and CYP2C9/2C19 genotypes on dose-adjusted steady-state serum concentrations of valproic acid—a large-scale study based on naturalistic therapeutic drug monitoring data. European Journal of Clinical Pharmacology. 72(9). 1099–1104. 29 indexed citations
13.
Haslemo, Tore, et al.. (2015). 4β‐hydroxycholesterol correlates with dose but not steady‐state concentration of carbamazepine: indication of intestinal CYP3A in biomarker formation?. British Journal of Clinical Pharmacology. 81(2). 269–276. 30 indexed citations
14.
Mannheimer, Buster, Tore Haslemo, Jonatan D. Lindh, Erik Eliasson, & Espen Molden. (2015). Risperidone and Venlafaxine Metabolic Ratios Strongly Predict a CYP2D6 Poor Metabolizing Genotype. Therapeutic Drug Monitoring. 38(1). 127–134. 28 indexed citations
15.
Haslemo, Tore, Irena Loryan, N. Ueda, et al.. (2012). UGT1A4*3 Encodes Significantly Increased Glucuronidation of Olanzapine in Patients on Maintenance Treatment and in Recombinant Systems. Clinical Pharmacology & Therapeutics. 92(2). 221–227. 28 indexed citations
16.
Solberg, Dag Kristen, Tore Haslemo, & Helge Refsum. (2012). Psykofarmakologisk poliklinikk. Tidsskrift for Den norske legeforening. 132(9). 1065–1067. 1 indexed citations
17.
Haslemo, Tore, et al.. (2012). Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients. The Pharmacogenomics Journal. 13(6). 544–550. 25 indexed citations
18.
Haslemo, Tore, Helge Refsum, & Espen Molden. (2010). The effect of ethinylestradiol‐containing contraceptives on the serum concentration of olanzapine and N‐desmethyl olanzapine. British Journal of Clinical Pharmacology. 71(4). 611–615. 12 indexed citations
19.
Haslemo, Tore, et al.. (2006). The effect of variable cigarette consumption on the interaction with clozapine and olanzapine. European Journal of Clinical Pharmacology. 62(12). 1049–1053. 124 indexed citations
20.
Haslemo, Tore, et al.. (2006). The Complexity of Active Metabolites in Therapeutic Drug Monitoring of Psychotropic Drugs. Pharmacopsychiatry. 39(4). 121–127. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Werner Steimer Breakdown of academic impact, for papers by Margaret T. Susce Breakdown of academic impact, for papers by J. Brockmöller Breakdown of academic impact, for papers by Sara Ramos Breakdown of academic impact, for papers by Roos van Westrhenen Breakdown of academic impact, for papers by Kazuo Mihara Breakdown of academic impact, for papers by Ida Rudberg Breakdown of academic impact, for papers by Josiah D. Allen Breakdown of academic impact, for papers by Nada Božina Breakdown of academic impact, for papers by Pablo Zubiaur
Rankless by CCL
2026